1 Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+

- 2
- 3 Nadia Shobnam^{1,+}, Grace Ratley1,+, Sarini Saksena^{1,+}, Manoj Yadav¹, Prem Prashant
- 4 Chaudhary¹, Ashleigh A Sun¹, Katherine N Howe², Manasi Gadkari³, Luis M Franco³, Sundar
- 5 Ganesan⁴, Katelyn J McCann³, Amy P Hsu³, Kishore Kanakabandi⁵, Stacy Ricklefs⁵, Justin
- 6 Lack⁶, Weiming Yu⁶, Morgan Similuk and Magdalena A Walkiewicz, for the NIAID Centralized
- 7 Sequencing Program⁷, Donna D Gardner⁸, Kelly Barta⁹, Kathryn Tullos⁹, and Ian A Myles¹.
- 8
- 9 ¹Laboratory of Clinical Immunology and Microbiology (LCIM), Epithelial Therapeutics Unit,
- 10 National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
- 11 (NIH), Bethesda MD.
- 12 ²LCIM, NIAID, NIH, Bethesda MD
- 13 ³Functional Immunogenomics Section, Systemic Autoimmunity Branch, National Institute of
- 14 Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
- ⁴Biological Imaging Section, Research Technology Branch, NIAID, NIH, Bethesda, MD
- ⁵Genomic Research Section, Research Technologies Branch (RTB), Rocky Mountain
 Laboratories, NIAID, NIH, Hamilton, MT
- ⁶Integrated Data Science Section, RTB, NIAID, NIH, Bethesda, MD
- ⁷Lymphocyte Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda,
 MD
- 21 ⁸Centralized Sequencing Program, Division of Intramural Research, NIAID, Bethesda, MD
- 22 ⁹Allergy & Asthma Network, Fairfax, Virginia
- 23 ¹⁰International Topical Steroid Awareness Network, Dacula, Georgia
- 24
- 25 + denotes equal contribution
- 26 * Corresponding author: mylesi@niaid.nih.gov
- 27
- 28
- _--
- 29

30 Abstract

31 Background:

Topical corticosteroids (TCS) are first-line therapies for numerous skin conditions. Topical Steroid Withdrawal (TSW) is a controversial diagnosis advocated by patients with prolonged TCS exposure who report severe systemic reactions upon treatment cessation. However, to date there have been no systematic clinical or mechanistic studies to distinguish TSW from other eczematous disorders.

37

38 Methods:

A re-analysis of a previous survey with eczematous skin disease was performed to evaluate potential TSW distinguishing symptoms. We subsequently conducted a pilot study of 16 patients fitting the proposed diagnostic criteria. We then performed: tissue metabolomics, transcriptomics, and immunostaining on skin biopsies; serum metabolomics and cytokine assessments; shotgun metagenomics on microbiome skin swabs; genome sequencing; followed by functional, mechanistic studies using human skin cell lines and mice.

45

46 **Results:**

47 Clinically distinct TSW symptoms included burning, flushing, and thermodysregulation. 48 Metabolomics and transcriptomics both implicated elevated NAD+ oxidation stemming from 49 increased expression of mitochondrial complex I and conversion of tryptophan into kynurenine 50 metabolites. These abnormalities were induced by glucocorticoid exposure both *in vitro* and in a 51 cohort of healthy controls (N=19) exposed to TCS. Targeting complex I via either metformin or

the herbal compound berberine improved outcomes in both cell culture and in an open-label caseseries for patients with TSW.

54

55 Conclusion:

56 Taken together, our results suggest that TSW has a distinct dermatopathology. While future 57 studies are needed to validate these results in larger cohorts, this work provides the first 58 mechanistic evaluation into TSW pathology, and offers insights into clinical identification, 59 pharmacogenomic candidates, and directed therapeutic strategies.

60

61

62 Introduction

Topical steroids are first-line therapies for atopic dermatitis (AD) and other inflammatory 63 dermatological conditions¹. Although more accurately described as glucocorticoids, topical 64 65 corticosteroids (TCS) is the more common clinical term. In recent decades, there has been a concerning rise in reports of severe systemic adverse reactions due to long-term use and abrupt 66 cessation of TCS (commonly referred to as Topical Steroid Withdrawal; TSW)². Although no 67 formal diagnostic criteria for TSW exist, reports of patients experiencing TSW are very common 68 online³. Initial reports concluded that TSW was limited to exposed areas for patients who 69 applied high-potency TCS to the face or genitals⁴. However, subsequent case series have better 70 71 identified the ways in which TSW may be different from AD, contact dermatitis, or other dermatoses^{2,5-7}, including disease manifestations on regions of the body where TCS were never 72 73 applied. Although resolution may take months to years, improvement is seen through avoidance 74 of TCS therapy, further suggesting that TSW is a distinct clinical entity rather than a flare of the underlying dermatoses⁸. 75

76

Although some have labeled the patient concerns as "steroid phobia"⁹, there have been no 77 systematic clinical or mechanistic studies to either refute or support TSW as molecularly distinct 78 79 from other dermatopathies. Herein, we report a re-analysis of a previous survey of 1,889 adults with eczematous skin disorders⁷ to clinically distinguish those that self-diagnosed with TSW 80 from those that denied having TSW. We then report the results of a pilot study of 16 patients 81 with symptoms consistent with TSW. Using multi-omics analysis of serum and skin samples we 82 83 identified increased vitamin B3 (nicotinic acid; NAD+) oxidation stemming from overexpression of known NAD+ producers^{10,11} such as mitochondrial complex I. Open-label treatment with anti-84

complex I medications (metformin or the "herbal metformin" berberine) led to notable
improvements in symptoms. Our work represents the first investigation into the pathogenesis of
TSW resulting in a promising targeted therapy.

- 88
- 89 **Results**

90 Patients with TSW have symptoms distinct from atopic dermatitis

Reanalysis of a previously published survey of patients with eczematous skin disease⁷ identified 91 92 worsening skin symptoms despite TCS use as most predictive of self-diagnosed TSW compared 93 to those with eczematous skin disease who denied having TSW (Fig. 1A; Fig. S1A). Worsening 94 signs may include reduced TCS effectiveness, a need for higher potency, spreading rash despite 95 treatment, or new-onset symptoms of temperature dysregulation and full body redness/burning 96 (Fig. 1A). Peak itch intensity and sleep disturbance were significantly higher in those affirming 97 TSW (Fig. 1B). However, there were no consistent, significant differences in body site for either severity (Fig. S1B) or application site (Fig. 1A). The dryness and oozing scores typically 98 collected for the Patient Oriented SCORing Atopic Dermatitis (PO-SCORAD¹²) severity metric 99 100 were inversely associated with TSW (Fig. 1A), however a greater degree of redness, scratching, 101 swelling, and thickening were seen in TSW (Fig. S1C). Skin specific symptoms with a greater 102 than 80% prevalence that are distinct from AD were deemed as major criteria while the 103 remainder were utilized as minor criteria (Fig. 1C). Twenty-five percent of patients reported all 104 related symptoms, while the combination of >1 major and >3 minor offered >90% sensitivity for 105 capturing those reporting TSW in the survey (Fig. 1C). Nearly 25% of patients reported 106 symptoms lasting longer than 3 years after discontinuation of TCS (Fig. 1D).

107

Although many reports imply that TSW is limited to the application of high-potency 108 glucocorticoids to the face or genitals^{4,13}, we enrolled a cohort (N = 16) who each experienced 109 110 full-body disease, including areas that had never been directly treated with TCS (Fig. S1D; Table 111 S1). Patients described full body redness, flushing, and anhidrosis (Fig. 1E; redacted per 112 medRxiv policies) occurring 4-6 weeks after discontinuation of TCS, which: tended to spare the nose (Fig. 1F; termed "headlamp sign"¹⁴; redacted per medRxiv policies), palms, and soles (Fig. 113 114 1F; redacted per medRxiv policies); and often formed "red sleeves" on the arms (Fig. 1G; 115 redacted per medRxiv policies). Additional symptoms included: subjective temperature 116 changes; stabbing neuropathic pain (termed "zingers" by patients; Fig. S1D); loose skin over the 117 flexor surfaces ("elephant wrinkles"; Fig. 1H; redacted per medRxiv policies); hair loss (Fig. 1I; 118 redacted per medRxiv policies); and substantial skin shedding (Fig. 1J- redacted per medRxiv 119 policies; Fig. S1D).

120

121 Serum metabolomics suggest systemic lipid dysregulation

Serum metabolomics for patients with TSW was compared to healthy volunteers (HV; N = 11), 122 123 and patients with AD who did not report symptoms of TSW (N = 10). Although matched for sex 124 and ethnicity, the TSW cohort was slightly older (mean 37.1 years) than AD (26 years) and HV 125 (25 years; Table S1; redacted per medRxiv policies). Significant differences were seen under 126 global similarity analysis but not for any specific identifiable metabolites (Fig. S2A-D). However, collating the results into MetaboAnalyst pathway analysis¹⁵ suggested patients with 127 128 TSW had significant deficiencies in the sphingolipid and urea cycle amino acid pathways (Fig. 129 S2E) compared to both HV and AD. Patients with TSW had significant overabundance of

metabolites in several pathways, including glycerophospholipids and C21-steroid hormones
including cortisol (Fig. S2F; Fig. S3).

132

Markers of dysbiosis and inflammation in TSW were similar to those previously described in
atopic dermatitis

135 Evaluation of the microbiome signatures in TSW revealed significant differences from HV in bacterial speciation at the genus level (Fig. 2A-B; Fig. S4A). Similar to AD¹⁶, there was a 136 137 predominance of Staphylococcal species, particularly S. aureus, burden (Fig. 2C) and reduced alpha bacterial diversity (Fig. 2D). Less robust differences with respect to HV were seen in 138 fungal speciation, with results again similar to those described for AD (Fig. 2E; Fig. S4B)¹⁷. 139 140 Virome signatures demonstrated an increased burden of viruses associated with fungal and 141 bacterial taxa (Fig. S4C) while functional metagenomics revealed global differences (Fig. 2F) 142 that were dominated by transcripts associated with Staphylococcus infection (Fig. S5A-B).

143

Like AD¹⁸, preliminary characterization of cell infiltrates were primarily CD4+ and CD8+ Tcells, as well as CD68+ monocytes (Fig. S5C); these immune cells were detectable in thin sections of skin biopsies for patients with TSW but required 3-dimensional volume analysis to detect in HV samples (Fig. S5D; Movie S1). For 11 of the patients in the cohort, IgE levels were elevated (Fig. 2G). Consistent with reported utility of dupilumab in TSW¹⁹, serum cytokine analysis indicated significantly increased levels of interleukin (IL-) 4 and IL-13, as well as proinflammatory IL-6 and CCL13 (Fig. 2H; Table S2).

151

152 Metabolomics implicates vitamin B3 metabolism

Skin metabolomics was performed using MALDI-imaging mass spectrometry²⁰, which identifies 153 154 metabolites in space (example shown in Fig. 3A). Ranking the abundance of metabolites that 155 could be identified using m/z and collisional cross section (CCS) revealed distinctions between TSW and HV (Fig. 3B). Using MetaboAnalyst¹⁵ to contrast TSW with both HV and AD 156 157 identified a significant increase in vitamin B3 (nicotinate and nicotinamide) metabolism (Fig. 3C). Several pathways were downregulated compared to the HV and AD cohorts, most 158 159 prominently tryptophan metabolism (Fig. 3D). Of note, nicotinic acid is a derivative of 160 tryptophan through a process that generates the known neuropathologic, and anticholinergic 161 intermediate kynurenine via the enzymes indoleamine 2,3-dixygenase (IDO) and tryptophan 2,3dioxygenase $(TDO)^{10}$. Consistent with the known interaction between NAD+ and the itch 162 regulating transient receptor potential (TRP) family ion channels^{21,22}, staining a subset of patients 163 164 and controls for expression of TRPA1 revealed enhanced dermal, but not total, expression (Fig. 165 S5E-F).

166

167 RNAseq suggests mitochondrial dysfunctionis present in TSW

168 Biopsies subjected to RNAseq identified cell cycle and neurodegeneration as the most 169 distinguishing pathways when comparing TSW to HV (Fig. S6A). The neurodegeneration 170 pathway includes *Wnt* signaling (Fig. 4A) which has been linked to AD previously and would be expected to produce increased cell proliferation²³. Several mitochondrial complexes were also 171 172 upregulated in patients with TSW, particularly complex I (Fig. 4B) which produces NAD+ as a 173 byproduct. Several other aspects of nicotinate metabolism were upregulated in TSW (Fig. S6B). 174 Opposing expression of *IDO2* and *TDO2* was seen between TSW and controls (Fig. 4C; full image in Fig. S6C). STRING analysis²⁴ demonstrated a strong signal for histone modifying and 175

DNA processing pathways but were most strongly linked to proton motive force in ATP
synthesis (Fig. S6D). Activation of inflammatory pathways known to respond to upregulations in
the oxidative stress pathways (Fig. S6A) was evident for MAP kinase (Fig. S7A), JAK-STAT
(Fig. S7B), NFκB (Fig. S8A), and T-cell receptor signaling (Fig. S8B).

180

181 Nicotinic acid and clobetasol exposure impact stem cell metabolism

Although niacin and nicotinic acid are known to induce skin flushing²⁵, most research into the 182 183 skin effects of niacin has focused on dietary intake. Topical application of nicotinic acid to 184 mouse ears yielded a dose-dependent increase in swelling (Fig. 5A), but with redness that was 185 below the mouse hairline (Fig. 5B). This finding is distinct from the standard murine models of 186 AD such as MC903, which induce dermatitis on the entire ear (Fig. S9A). Combining the prior reports of nasal, palmar, and plantar sparing, the protracted resolution¹⁴, and murine disease 187 188 limited to areas with hair (Fig. 5B) suggested a possible role for stem cells in the pathology of 189 TSW given that these cells reside at the base of each hair follicle and serve as progenitors for replenishing other skin cells²⁶. 190

191

Similar to prior reports²⁷, incubation of human follicular stem cells (HFSC) with nicotinic acid led to enhanced proliferation (Fig. 5C). Exposure to the commonly prescribed, high-potency glucocorticoid clobetasol also significantly increased HFSC proliferation (Fig. 5D). Functional metabolic analysis of HFSC indicated clobetasol exposure increased maximal extracellular acidification rate (ECAR; a measurement of glycolysis; Fig. 5E, Fig. S9B) but not resting oxygen consumption rate (OCR; a proxy for oxidative phosphorylation; Fig. 5F, Fig. S9C).

199 steroids from the media after clobetasol exposure impacted vitamin B3 and other metabolic 200 pathways including the TCA cycle (Fig. 5G; Fig. S9D). Differences between continuous 201 glucocorticoid exposure and steroid withdrawal were also evident for human primary 202 keratinocytes, fibroblasts, and Schwann nerve cells (Fig. 5G; Fig. S9E-G).

203

204 These results suggested that TSW pathology may represent an overactivation of complex I 205 driving up NAD+ oxidation, either through increased complex I expression or increased NADH 206 availability via tryptophan metabolism (Fig. S10A). Metformin is a known blocker of complex I^{11} , has pre-clinical efficacy in models of AD²⁸, and reduces the conversion of tryptophan to 207 208 kynurenine²⁹. Similarly, berberine is the main ingredient in the traditional Chinese medicine, Wu Mei Wan, previously shown to improve TSW³⁰; berberine is also a known complex I 209 inhibitor with similar uses as metformin³¹. Metformin treatment of HFSC prevented 210 211 hyperproliferation (Fig. 5D) as well as the alterations in basal OCR and ECAR (Fig. 5E-F, Fig. 212 5H-I, Fig. S9B-C). Berberine did not alter proliferation (Fig. 5D) or basal ECAR (Fig. 5I, Fig. 213 S9B) but was a more potent inhibitor of OCR (Fig. 5F, Fig. 5H, Fig. S9C). Diluting berberine to 214 as low as 0.6uM had inhibitory activity without a strong coloration (Fig. 5H, Fig. S10B).

215

216 Topical glucocorticoids alter mitochondrial transcription pathways

Nineteen healthy controls aged 18-64 were treated with the topical glucocorticoid methylprednisolone aceponate. Skin biopsies were taken prior to exposure, then again 4 hours after topical application. RNAseq identified numerous significant differences (Fig. S11A) concentrated in the keratinocyte differentiation pathways (Fig. S11B). Mitochondrial complexes, especially the complex I, NAD+ producing enzyme, ubiquinone reductase were

significantly upregulated by topical glucocorticoid exposure (Fig. S11C-D). Impacts on *Wnt* and
tryptophan metabolism were evident, but less robust than for TSW (Fig. S12A-B).

224

225 Complex I Targeting Therapies Improve TSW Symptoms

Patients in the cohort were informed about the potential utility of metformin and berberine and provided the analysis by the commercial outlet ConsumerLabs identifying that Natural Factors WellBetX and Solaray supplement brands contained the indicated amount of berberine without harmful contaminants. Three patients elected to take metformin through their primary care providers, 9 elected to take berberine purchased online, 2 made no changes in treatment, while 1

231 opted for alternate treatments (Table S1). No serious complications were reported (Table S1).

232

After 3-5 months of use, subjective overall improvement between 5% and 80% was reported for both interventions (Fig. 5J), with non-significantly greater improvement reported for those on berberine. Patients initially noted their skin becoming "softer" and/or "smoother" followed by an "inside out" resolution of itch in which the bone-deep itch resolved before the superficial itch. Rashes improved in both groups (Fig. 5K; redacted per medRxiv policies). Patients still reported flares related to known triggers such as infection, stress, or temperature change; however, these flares were described as of lower severity or shorter duration.

240

241 DNA variants with differentially expressed transcripts in TSW included PAX6 and FMO2

Genome sequencing only identified the highly variable *TTN* as the gene with variants of uncertain significance (VUS) across the cohort (Fig. S13A-B). Expanded analysis of the genome identified 206 genes with DNA variants present in at least 12 of the 16 participants with

245 combined annotation dependent depletion (CADD) scores greater than 20 (a predictor of how 246 deleterious to protein function a variant might be; Fig. S13C). STRING analysis of these 247 variants suggested the corresponding genes were enriched for involvement in cell adhesion, 248 neuron development, and mitochondrial depletion (Fig. S13D-F). Comparing the variant list 249 with the RNAseq results indicated that genes which contained DNA variants and differentially expressed transcripts were led by the known modulator of NADPH metabolism $FMO2^{32}$ and 250 PAX6, which may mediate AD-relevant pathways in epithelial-to-mesenchymal transition^{33,34} 251 252 (Fig. S13G-I). Sequence analysis of the mitochondrial genomes did not identify any common 253 non-synonymous variants within our cohort (Table S3).

254

255 Discussion

Our results indicate that TSW is a distinct, iatrogenic dermatopathy deserving of further investigation. In this study, we propose diagnostic criteria to separate TSW from other eczematous skin disorders, provide early insights into cellular pathogenesis, identify candidate DNA variants, and describe the results from an open-label case series of two molecularly targeted therapies. Although the severity of skin disease was greater in our TSW cohort than their AD comparators, our findings are distinct from the numerous reports of lipid-centric defects seen in severe AD^{35} .

263

Our working hypothesis of TCS induced complex I hyperactivity in follicular stem cells is supported by the established effects of glucocorticoids on mitochondria³⁶ and the clinical data detailing the distribution and duration of TSW symptoms^{2,5-7}. In some individuals, prolonged use may result in a form of endogenous chemical irritation due to overproduction of oxidized

NADH (NAD+). The enhanced NADH production generated by tryptophan degradation results
 in an increase in neuro-toxic kynurenine metabolites via the corticosteroid-responsive enzymes
 IDO and TDO¹⁰. We hypothesize that epigenetic changes may underly the protracted nature of
 TSW recovery, however cell specific analysis will be needed to further elucidate our findings.

272

A hypothesis predicated on NAD+ is consistent with each of the proposed phases of TSW⁷: the initial rise in NAD+ combined with the resultant anticholinergic effects of kynurenic mediators may lead to the early signs of flushing, anhidrosis, palpitations, neuralgia, and vision changes³⁷. Subsequent Wnt overactivity, mitochondrial inflammatory reactive oxygen species, and TRP receptor activation would be expected to induce desquamation, pruritus, skin proliferation, changes in temperature sensation, and may make those with TSW more susceptible to effects of chemical triggers associated with pruritic skin diseases³⁸.

280

281 Our work suggests clinical insights for practitioners treating patients experiencing worsening 282 eczematous skin disease despite >4 months of TCS treatment. For example, the prior claims of disease limited to the face or genitals⁴ are not supported by our data and should not guide 283 284 diagnosis. Instead, patients with the identified TSW predictive symptoms should be evaluated 285 for the diagnosis and considered for treatment using mitochondrial complex I inhibitors; 286 however, expanded formal trials will be needed to confirm the safety and efficacy of these 287 treatments. Although topical berberine was not attempted in this study, the efficacious 288 concentrations in vitro are akin to dissolving one 500 mg capsule in a liter of water and then 289 adding ¹/₄ cup of the resultant solution to a standard 60-gallon bathtub as is done with bleach

290 baths in AD^{39} . Exposure to heat may also be a speculative intervention given higher 291 temperatures preferentially inhibit mitochondrial complex I^{40} .

292

293 Our work is limited in several ways. First, querying TSW-specific symptoms from eczematous 294 patients who deny having TSW will be required to validate the diagnostic criteria through 295 calculating specificity and accuracy. The small pilot enrollment and open label case series may 296 not fully capture either the pathology or treatment response for a disorder with a reported 297 population of the scale of TSW. Our global subjective assessment of TSW improvement should be replaced by prospective severity indices specific to TSW which incorporate scores for 298 299 thermodysregulation, burning, and flushing. Additionally, larger studies will be needed to test 300 whether the proposed DNA variants are specifically associated with TSW and, if so, what the 301 biologic consequences of those variants might be. Similarly, the statistical association with 302 Protopic (tacrolimus; Fig. 1A) will require targeted evaluation.

303

Importantly, while our case series suggests expanded clinical assessments are warranted, no patient reported complete resolution of symptoms. While prolonged treatment may yield continued improvement, preemptive caution may be warranted for exposures longer than 4 consecutive months and identifying preventive strategies and predictive factors should remain paramount.

309

310 Acknowledgments:

311 This work was supported by the Division of Intramural Research (DIR) of the National Institute312 of Allergy and Infectious Diseases, NIH. LMF and MG are supported by the Intramural

Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
NIAID Centralized Sequencing Program contributor information: Rajarshi Ghosh, Bryce Seifert,
Mari Tokita, Jia Yan, Colleen Jodarski, Michael Kamen, Rachel Gore Moses, Nadjalisse
Reynolds-Lallement, Katie Lewis, Sarah Bannon, Adrienne Borges, Nicole Gentile, Katya
Damskey, Sophie Byers, Halyn Orellana, Sruthi Srinivasan. Allergy & Asthma Network has
received funding from Sanofi, Regeneron, Genentech, Pfizer, and Novartis for unbranded disease
awareness and education; such funding was not relevant to the presented research.

320 Figure Legends:

321 Figure 1: Topical Steroid Withdrawal (TSW) is distinguishable from other eczematous skin 322 diseases. (A) Lasso regression model of previously reported survey results from 1,889 individuals with eczematous skin disease⁷ establishing the responses that are most predictive of 323 324 self-identified TSW. Results separated by over-the-counter hydrocortisone (HC) versus 325 prescription topical steroids (TS). (B) Intensity of itch and sleep disruption for the respondents 326 affirming TSW versus those denying such diagnosis. (C) Proposed diagnostic criteria derivation 327 evaluating the sensitivity (Sens.) for number of reported Major and Minor criteria extracted from 328 survey from respondents reporting suffering from TSW (N=1,486). (D) Time to symptom of 329 TSW symptoms as reported by respondents (N=1,486). (E-I) Representative images of TSW 330 associated symptoms; although images provided with explicit permission and consent, medRxiv 331 does not allow images of body parts and thus these images have been removed. The final 332 publication will display these images.

333

Figure 2: Microbiome and Th2 cytokine signatures in TSW differ from healthy controls. 334 335 Shotgun metagenomic sequencing was performed on skin swabs from patients with TSW (N=16) versus healthy volunteers (N=7). (A) Speciation at genre level with most abundant taxa indicated 336 (full list in Fig. S4A). (B) Similarity plot as measured by NMDS (non-metric multidimensional 337 338 scaling) for genre-level bacterial analysis. (C) Normalized counts for Staphylococcus aureus. (D) 339 Chao1 alpha-diversity index. (E-F) Speciation and NMDS for fungal genre. (G) IgE levels (mean 340 + SD) for TSW cohort (dotted line indicates upper limit of normal for our hospital). (H) Serum 341 cytokine levels for HV, TSW and patients with atopic dermatitis without history of TSW (AD) 342 for interleukin (IL-) 13, IL-6, CCL13, and IL-4. Significance adjusted for three-way comparison, but not the full number of cytokines analyzed. * = p value <0.05, ns = not significant, other p 343 344 values indicated.

345

346 Figure 3: Skin from patients with TSW demonstrates disruptions in Vitamin B3 and 347 Tryptophan metabolism. Skin biopsy samples from patients with topical steroid withdrawal 348 (TSW; N=16), Atopic Dermatitis (AD; N=10), and healthy volunteers (HV; N=11) underwent 349 MALDI-imaging mass spec. (A) Representative image for distribution of metabolite at 772.5213 350 m/z for HV and TSW (B) Intensity values for metabolites identifiable through combination of 351 m/z and collisional cross-section for HV and TSW. (C-D) MetaboAnalyst pathway analysis for metabolites ranked by how predictive of TSW they were compared with both HV and AD 352 353 cohorts (C) and metabolites ranked by ROC value (receiver operating characteristic) for the HV 354 and AD cohorts compared to TSW (D). Bolding indicates pathways not identified as distinctive 355 for AD relative to HV.

356

Figure 4: Skin from patients with TSW demonstrates disruptions in Niacin related
metabolic pathways. Skin biopsy samples from patients with topical steroid withdrawal (TSW;
N=16) and healthy volunteers (HV; N=11) underwent RNAseq analysis. (A-C) KEGG pathway
analysis for *Wnt* signaling (A), Oxidative phosphorylation (B), and Nicotinate and Nicotinamide

metabolism (C; full image in Fig. S6B). Superimposed log₁₀ fold change, green indicates
product is more abundant in HV, red indicates product is more abundant in patients with TSW.

364 Figure 5: Steroid withdrawal induces mitochondrial associated niacin overproduction in 365 human skin cells. (A-B) Mice were treated for 8 days with daily topical application of nicotinic acid. Resultant ear thickness (A) and representative image of redness below shaved hairline (B) 366 367 are shown. (C) Human follicular stem cells (HFSC) exposed to increasing doses of nicotinic 368 acid, scale bars indicate 2mm. (D) Total cell count for HFSC incubated in clobetasol for 48 hours (Steroid), clobetasol for 24 hours followed by normal media for 24 hours (Steroid 369 370 withdrawal), or under steroid conditions with 10uM for metformin or berberine. Dots indicate 371 replicate wells. (E-F) HFSC under mitochondrial stress test for Seahorse assay; indicating basal 372 extracellular acidification rate (ECAR; a measurement of glycolysis) and basal oxygen 373 consumption rate (OCR; a proxy for oxidative phosphorylation) for cells incubated as in panel D. 374 (G) MetaboAnalyst pathway derive index of pathway significance for HFSC, keratinocytes (KC), fibroblasts (FB), or Schwann cells (Sch.) under steroid (S) and steroid withdrawal (W) 375 conditions as measured by imaging mass spec. (H) Basal OCR and ECAR for HFSC incubated 376 with metformin or berberine (but no glucocorticoids) for 24 hours before Seahorse analysis. (J) 377 Response from patients for global assessment of overall improvement after 3-5 months of 378 379 treatment with indicated intervention. Open diamond indicates patient who started on metformin 380 for 2 months, then switched to berberine for 2 months. Open circle indicates patient that 381 discontinued berberine after 4 weeks when she discovered she was pregnant. Open triangle 382 indicates a patient who used both berberine and 'activated plasma'. Closed square indicate 383 patient with a multitude of various interventions (See Table S3 for more details). One participant was loss to follow up. (K) Representative images of improvement in patients who used 384 385 berberine; although images provided with explicit permission and consent, medRxiv does not 386 allow images of body parts and thus these images have been removed. The final publication will 387 display these images. Data represent 3 independent experiments (A-I) and are indicated by mean 388 + SEM.

389

390 REFERENCES

- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71(1):116-32. DOI: 10.1016/j.jaad.2014.03.023.
- Hwang J, Lio PA. Topical corticosteroid withdrawal ('steroid addiction'): an update of a systematic review. J Dermatolog Treat 2022;33(3):1293-1298. DOI: 10.1080/09546634.2021.1882659.
- 3973.Bowe S, Masterson S, Murray G, Haugh I. Topical steroid withdrawal through the lens of398social media. Clin Exp Dermatol 2022;47(8):1554-1557. DOI: 10.1111/ced.15194.
- Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid
 withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. J
 Am Acad Dermatol 2015;72(3):541-549 e2. DOI: 10.1016/j.jaad.2014.11.024.
- 402 5. Sheary B, Harris MF. Cessation of Long-term Topical Steroids in Adult Atopic Dermatitis:
 403 A Prospective Cohort Study. Dermatitis 2020;31(5):316-320. DOI:
 404 10.1097/DER.0000000000602.
- 4056.Brookes TS, Barlow R, Mohandas P, Bewley A. Topical steroid withdrawal: an emerging406clinical problem. Clin Exp Dermatol 2023;48(9):1007-1011. DOI: 10.1093/ced/llad161.
- 407 7. Barta K, Fonacier LS, Hart M, et al. Corticosteroid exposure and cumulative effects in patients with eczema: Results from a patient survey. Ann Allergy Asthma Immunol 2023;130(1):93-99 e10. DOI: 10.1016/j.anai.2022.09.031.
- 410 8. Feschuk AM, Pratt ME. Topical steroid withdrawal syndrome in a mother and son: A
 411 case report. SAGE Open Med Case Rep 2023;11:2050313X231164268. DOI:
 412 10.1177/2050313X231164268.
- 413 9. Finnegan P, Murphy M, O'Connor C. #corticophobia: a review on online misinformation
 414 related to topical steroids. Clin Exp Dermatol 2023;48(2):112-115. DOI:
 415 10.1093/ced/llac019.
- 416 10. Qin Y, Wang N, Zhang X, Han X, Zhai X, Lu Y. IDO and TDO as a potential therapeutic target in different types of depression. Metab Brain Dis 2018;33(6):1787-1800. DOI: 10.1007/s11011-018-0290-7.
- 41911.Vial G, Detaille D, Guigas B. Role of Mitochondria in the Mechanism(s) of Action of420Metformin. Front Endocrinol (Lausanne) 2019;10:294. DOI: 10.3389/fendo.2019.00294.
- 421 12. Faye O, Meledie N'Djong AP, Diadie S, et al. Validation of the Patient-Oriented
 422 SCORing for Atopic Dermatitis tool for black skin. J Eur Acad Dermatol Venereol
 423 2020;34(4):795-799. DOI: 10.1111/jdv.15999.
- 42413.Spergel JM, Leung DYM. Topical steroid withdrawal syndrome: Should we worry? Ann425Allergy Asthma Immunol 2023;130(1):8. DOI: 10.1016/j.anai.2022.09.005.
- 42614.Sheary B. Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use.427Dermatitis 2018;29(4):213-218. DOI: 10.1097/DER.0000000000387.
- 428 15. Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw
 429 spectra and functional insights. Nucleic Acids Res 2021;49(W1):W388-W396. DOI:
 430 10.1093/nar/gkab382.
- 431 16. Gough P, Zeldin J, Myles IA. Assessing microbial manipulation and environmental 432 pollutants in the pathogenesis of psoriasis. Front Immunol 2022;13:1094376. DOI: 433 10.3389/fimmu.2022.1094376.
- 434 17. Tao R, Li R, Wang R. Dysbiosis of skin mycobiome in atopic dermatitis. Mycoses
 435 2022;65(3):285-293. DOI: 10.1111/myc.13402.
- 43618.Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food437allergy. Allergol Int 2020;69(2):204-214. DOI: 10.1016/j.alit.2019.08.013.

- 438 19. Arnold KA, Treister AD, Lio PA. Dupilumab in the management of topical corticosteroid
 439 withdrawal in atopic dermatitis: A retrospective case series. JAAD Case Rep
 440 2018;4(9):860-862. DOI: 10.1016/j.jdcr.2018.06.012.
- Yadav M, Chaudhary PP, D'Souza BN, Spathies J, Myles IA. Impact of Skin Tissue
 Collection Method on Downstream MALDI-Imaging. Metabolites 2022;12(6). DOI:
 10.3390/metabo12060497.
- 444 21. Ma L, Lee BH, Mao R, et al. Nicotinic acid activates the capsaicin receptor TRPV1:
 445 Potential mechanism for cutaneous flushing. Arterioscler Thromb Vasc Biol 2014;34(6):1272-80. DOI: 10.1161/ATVBAHA.113.303346.
- 447 22. Arendt-Nielsen L, Carstens E, Proctor G, et al. The Role of TRP Channels in Nicotinic
 448 Provoked Pain and Irritation from the Oral Cavity and Throat: Translating Animal Data to
 449 Humans. Nicotine Tob Res 2022;24(12):1849-1860. DOI: 10.1093/ntr/ntac054.
- 450 23. Myles IA, Anderson ED, Earland NJ, et al. TNF overproduction impairs epithelial 451 staphylococcal response in hyper IgE syndrome. J Clin Invest 2018;128(8):3595-3604.
 452 DOI: 10.1172/JCI121486.
- 453 24. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-454 protein association networks and functional enrichment analyses for any sequenced 455 interest. Nucleic Acids Res 2023;51(D1):D638-D646. genome of DOI: 456 10.1093/nar/gkac1000.
- 45725.Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced458flushing. Int J Clin Pract 2009;63(9):1369-77. DOI: 10.1111/j.1742-1241.2009.02099.x.
- 459 26. Diaz-Garcia D, Filipova A, Garza-Veloz I, Martinez-Fierro ML. A Beginner's Introduction
 460 to Skin Stem Cells and Wound Healing. Int J Mol Sci 2021;22(20). DOI:
 461 10.3390/ijms222011030.
- 462 27. Tan CL, Chin T, Tan CYR, et al. Nicotinamide Metabolism Modulates the
 463 Proliferation/Differentiation Balance and Senescence of Human Primary Keratinocytes. J
 464 Invest Dermatol 2019;139(8):1638-1647 e3. DOI: 10.1016/j.jid.2019.02.005.
- 465 28. Choi SY, Lee C, Heo MJ, et al. Metformin ameliorates animal models of dermatitis.
 466 Inflammopharmacology 2020;28(5):1293-1300. DOI: 10.1007/s10787-020-00704-8.
- 467 29. Muzik O, Burghardt P, Yi Z, Kumar A, Seyoum B. Successful metformin treatment of 468 insulin resistance is associated with down-regulation of the kynurenine pathway. 469 Biochem Biophys Res Commun 2017;488(1):29-32. DOI: 10.1016/j.bbrc.2017.04.155.
- Wang Z, Wang ZZ, Geliebter J, Tiwari R, Li XM. Traditional Chinese medicine for food allergy and eczema. Ann Allergy Asthma Immunol 2021;126(6):639-654. DOI: 10.1016/j.anai.2020.12.002.
- 47331.Fang X, Wu H, Wei J, Miao R, Zhang Y, Tian J. Research progress on the
pharmacological effects of berberine targeting mitochondria. Front Endocrinol
(Lausanne) 2022;13:982145. DOI: 10.3389/fendo.2022.982145.
- 476 32. Bailleul G, Nicoll CR, Mascotti ML, Mattevi A, Fraaije MW. Ancestral reconstruction of 477 mammalian FMO1 enables structural determination, revealing unique features that 478 explain its catalytic properties. J Biol Chem 2021;296:100221. DOI: 479 10.1074/jbc.RA120.016297.
- 480 33. A, Liu K. Jin Μ. Gao D, Wang R, Sik Possible involvement of 481 TGF²beta²SMAD²mediated epithelial²mesenchymal transition in pro²metastatic 482 property of PAX6. Oncol Rep 2020;44(2):555-564. DOI: 10.3892/or.2020.7644.
- 483 34. Anderson ED, Alishahedani ME, Myles IA. Epithelial-Mesenchymal Transition in Atopy:
 484 A Mini-Review. Front Allergy 2020;1. DOI: 10.3389/falgy.2020.628381.
- 48535.Zhang L, Zeng Y, Sun J. Progress of metabolomics in atopic dermatitis: a systematic486review. J Dtsch Dermatol Ges 2023;21(3):229-236. DOI: 10.1111/ddg.14960.
- 487 36. Choi GE, Han HJ. Glucocorticoid impairs mitochondrial quality control in neurons.
 488 Neurobiol Dis 2021;152:105301. DOI: 10.1016/j.nbd.2021.105301.

- 489 37. Lopez-Alvarez J, Sevilla-Llewellyn-Jones J, Aguera-Ortiz L. Anticholinergic Drugs in
 490 Geriatric Psychopharmacology. Front Neurosci 2019;13:1309. DOI:
 491 10.3389/fnins.2019.01309.
- 492 38. Yadav M, Chaudhary PP, D'Souza BN, et al. Diisocyanates influence models of atopic
 493 dermatitis through direct activation of TRPA1. PLoS One 2023;18(3):e0282569. DOI:
 494 10.1371/journal.pone.0282569.
- 495 39. Panel AAJADG, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023
 496 American Academy of Allergy, Asthma and Immunology/American College of Allergy,
 497 Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and
 498 Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol
 499 2024;132(3):274-312. DOI: 10.1016/j.anai.2023.11.009.
- 500 40. Chretien D, Benit P, Ha HH, et al. Mitochondria are physiologically maintained at close 501 to 50 degrees C. PLoS Biol 2018;16(1):e2003992. DOI: 10.1371/journal.pbio.2003992.

502

503

504

505







Fig 4







А

